Amoeba : Amoéba announces the appointment of Pierre MORGON as censeur on the Board of Directors

PRESS RELEASE

AMOEBA ANNOUNCES THE APPOINTMENT OF PIERRE MORGON AS CENSEUR

ON THE BOARD OF DIRECTORS

Chassieu (France), December 17 2020 - 5.45 pm- AMOEBA (FR0011051598 - ALMIB), the Board of Directors of Amoeba, at its meeting of 17 December 2020, appointed Pierre Morgon as non-votingDirector with a view to proposing his candidacy as Director at the next General Meeting of Shareholders to be held in 2021. As a non-votingdirector, he will attend the next meetings of the Board of Directors in an advisory capacity, bringing his extensive experience and expertise to the Company.

Experiences and training

Pierre Morgon has over 30 years of experience in the global Life Sciences industry, especially specialty care, vaccines and immunotherapy, in management positions in multinational companies and as CEO of start-up companies.

He is a lecturer in several MBA programs and life sciences conferences, as well as at the Mass Challenge incubator in Switzerland where he also acts as a mentor for life sciences start-ups.

Currently, Pierre MORGON is CEO of MRGN Advisors, Regional Partner for Switzerland at Mérieux Equity Partners and Senior Vice-President International Business at CanSino Biologics.

He is also Chairman of the Boards of Directors of Theradiag, Eurocine Vaccines, MYCB1 and Health Technology Holding, as well as Non-Executive Director of the Boards of Directors of Vaccitech and Univercells.

He holds a doctorate in pharmacy, a master's degree in business law and a MBA. He is also an alumnus of ESSEC, INSEAD and IMD.

"I would like to thank Fabrice Plasson for the confidence he has shown in me by asking me to join Amoeba's Board of Directors. The company is in full expansion and the new applications of its technology in human health represent an exciting opportunity and challenge. I look forward to bringing my experience in life sciences, both in terms of development, partnerships and business development as well as governance" said Pierre MORGON.

"Pierre is a global reference in the field of vaccines and immunotherapies as well as in the entire value chain of the healthcare industry. It is a great pleasure to welcome him to our Board of Directors to benefit from his international vision (Chinese, European and American) in this sector. Pierre is also a recognized director of listed companies in Europe and an investment fund manager, with a perfect understanding of the challenges faced by companies such as Amoeba, which are undergoing strong acceleration," said Fabrice Plasson, Chairman and CEO of Amoeba.

Adresse : 38 Avenue des Frères Montgolfier, 69680 CHASSIEU	Tel: [phone] - Email: [e-mail]
Société Anonyme au capital de 311 578,38 €	Linkedin: @amoeba-nature - Twitter: @AmoebaNature
RCS Lyon 523 877 215	www.amoeba-nature.com

About AMOEBA:

Amoéba's ambition is to become a major player in the treatment of bacterial risk in the fields of water, healthcare and plant protection. Our biological solution is an alternative to chemical products widely used today. Amoéba is currently focusing on the market of industrial cooling towers estimated at €1.7Bn (1) on a global chemical biocide market for water treatment, evaluated at €21Bn (2) and on the biocontrol market for plant protection estimated globally at €1.6Bn (4). In the future, the Company is looking at developing new applications such as chronic wound care, estimated at € 751 million (3) in the USA. Sales of associated products with healthcare, biocides and crop protection are subject to the Company being granted local regulatory market authorizations. The Company is currently in a trial phase for biocidal and plant protection applications and does not market any products.

Created in 2010, based in Chassieu (Lyon, France) with a subsidiary in Canada and in the United States, Amoéba is quoted on Euronext Growth. The Company is a member of the BPIfrance Excellence network and is eligible for the PEA-PME SME equity savings plan setup. More information on www.amoeba-biocide.com.

(1): Amoéba data combined from sources: DRIRE 2013, Eurostat, ARHIA 2013

(2): Sources combined by Amoéba from water treaters, Freedonia, Eurostat et MarketsandMarkets

(3): BCC Research, "Markets for Advanced Wound Management Technologies," Wellesley, MA, 2017

(4): Biopesticides Worldwide Market 2013, CPL, Wallingford, UK

Contacts:
Amoéba	Calyptus
Valérie FILIATRE	Relations investisseurs & Presse
Directeur Général Adjoint	Grégory BOSSON / Mathieu CALLEUX
[phone]	[phone] /91
[e-mail]	[e-mail]

Disclaimer

This press release contains certain forward-looking statements concerning AMOEBA which are based on its own assumptions and hypothesis and on information that are available to us. However, AMOEBA gives no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the Universal Registration Document of AMOEBA filed with the French Financial Markets Authority (Autorité des Marchés Financiers) on April 30, 2020 under number D20-0416 (a copy of which is available on www.amoeba-biocide.com). The forward-looking statements contained in this press release are also subject to risks not yet known to AMOEBA or not currently considered material by AMOEBA. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of AMOEBA to be materially different from such forward-looking statements.

Adresse : 38 Avenue des Frères Montgolfier, 69680 CHASSIEU	Tel: [phone] - Email: [e-mail]
Société Anonyme au capital de 311 578,38 €	Linkedin: @amoeba-nature - Twitter: @AmoebaNature
RCS Lyon 523 877 215	www.amoeba-nature.com